Systems analysis of drug-induced receptor tyrosine kinase reprogramming following targeted mono- and combination anti-cancer therapy.
about
NRF2 Regulates HER2 and HER3 Signaling Pathway to Modulate Sensitivity to Targeted Immunotherapies.A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cells.Receptor Tyrosine Kinases — Expanding Horizons.Breast Cancer Cell Apoptosis is Synergistically Induced by Curcumin, Trastuzumab, and Glutathione Peroxidase-1 but Robustly Inhibited by Glial Cell Line-Derived Neurotrophic Factor.Multifunctional nanoparticles for co-delivery of paclitaxel and carboplatin against ovarian cancer by inactivating the JMJD3-HER2 axis.NRF2 Regulates HER1 Signaling Pathway to Modulate the Sensitivity of Ovarian Cancer Cells to Lapatinib and Erlotinib.
P2860
Systems analysis of drug-induced receptor tyrosine kinase reprogramming following targeted mono- and combination anti-cancer therapy.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Systems analysis of drug-induc ...... mbination anti-cancer therapy.
@en
Systems analysis of drug-induc ...... mbination anti-cancer therapy.
@nl
type
label
Systems analysis of drug-induc ...... mbination anti-cancer therapy.
@en
Systems analysis of drug-induc ...... mbination anti-cancer therapy.
@nl
prefLabel
Systems analysis of drug-induc ...... mbination anti-cancer therapy.
@en
Systems analysis of drug-induc ...... mbination anti-cancer therapy.
@nl
P2093
P2860
P356
P1433
P1476
Systems analysis of drug-induc ...... ombination anti-cancer therapy
@en
P2093
Alexey Goltsov
Hilal S Khalil
Huizhong Hu
James Bown
Simon P Langdon
Stylianos Kyriakidis
Tero Soininen
P2860
P304
P356
10.3390/CELLS3020563
P577
2014-06-10T00:00:00Z